Eleuterio Ferrannini, MD; Dr. Diamant; Dr. Barnett; Dr. Davies, PhD; Dr. Hanefeld, PhD
CME Released: 10/24/2011; Valid for credit through 10/24/2012
Despite the availability of multiple pharmacologic agents, the treatment of patients with type 2 diabetes mellitus remains suboptimal. Given the disease's high and increasing prevalence, the morbidity, mortality, and economic consequences of type 2 diabetes are a great burden to patients, healthcare systems, and society.
